Drug study to prevent relapse after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with a TP53 mutation.
- You had a stem cell transplant and your tests show no remaining cancer cells within 2 months after transplant.
- You are between 12 and 65 years old.
- You are in fairly good health (can care for yourself and expected to live at least 3 more months).
- You have not had severe graft-versus-host disease (GVHD), which is a condition where the donor's cells attack your body.
- You must be able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
This trial tests a combination of three medicines (sirolimus, ruxolitinib, and mycophenolate mofetil) to prevent graft-versus-host disease (a common complication after a stem cell transplant) in people who cannot take standard anti-rejection drugs. The goal is to find a safer alternative that still protects you from this complication.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.